BFRIW — Biofrontera Inc.

Summary of Biofrontera Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $17.1 million, a 36% increase year-over-year (YoY) and the highest quarterly revenue in company history.
• Full Year 2025 Revenue: $41.7 million, up 12% from $37.3 million in 2024.
• Adjusted EBITDA: Q4 adjusted EBITDA was $4.9 million, compared to negative $1.4 million in Q4 2024. Full-year adjusted EBITDA improved to negative $10.6 million from negative $15.3 million in 2024.
• Net Income: Q4 net income was $5.6 million, a significant improvement from a net loss of $1.4 million in Q4 2024. Full-year net loss narrowed to $10.5 million from $17.8 million in 2024.
• Gross Margin: Improved to 82% in Q4 2025 from 58% in Q4 2024, driven by a new earn-out structure from the strategic transaction with Biofrontera AG.

2. Strategic Updates and Business Highlights

• Acquisition of U.S. Rights: Biofrontera acquired all U.S. rights, approvals, and patents for Ameluz and RhodoLED from Biofrontera AG, enhancing its control over key assets.
• Regulatory Milestones: The FDA accepted a supplemental New Drug Application for Ameluz to treat superficial basal cell carcinoma (sBCC), with a PDUFA date set for September 28, 2026.
• Clinical Progress: Positive Phase III results for actinic keratosis (AK) on extremities and Phase II results for moderate to severe acne vulgaris were reported, with plans for NDA submissions in 2026.
• Operational Improvements: The company placed 85 new RhodoLED lamps in dermatology practices, increasing its installed base to approximately 745 lamps.

3. Forward Guidance and Outlook

• Gross Margin Expectations: Anticipated gross margins of 80% to 85% for 2026, with the expectation of consistent performance throughout the year.
• Cash Flow Breakeven: The company aims to achieve cash flow breakeven, supported by improved operational efficiencies and reduced costs from the new earn-out structure.

4. Bad News, Challenges, or Points of Concern

• Legal Expenses: SG&A expenses increased by $4 million, primarily due to legal costs related to patent claims, which could impact profitability.
• Net Loss: Despite improvements, the company reported a net loss for the year, indicating ongoing financial challenges.
• Patent Disputes: While a favorable decision was received in a patent dispute with Sun Pharma, the potential for further review poses ongoing risks.

5. Notable Q&A Insights

• Gross Margin Variability: Management indicated that gross margins may fluctuate slightly based on product mix but expect to start the year at around 82%.
• Strategic Focus: The company emphasized the effectiveness of its revamped commercial strategy and the positive trajectory of its clinical pipeline, which are seen as key drivers for future growth.

Overall, Biofrontera Inc. showcased strong financial performance in Q4 2025, driven by strategic acquisitions and clinical advancements, while also addressing ongoing challenges related to legal expenses and net losses. The outlook for 2026 appears optimistic with expectations of improved gross margins and a focus on achieving cash flow breakeven.